SL-Cloud: A Cloud-based resource to support synthetic lethal interaction discovery.

cancer dependency cancer genomics cloud computing functional genomics synthetic lethality systems biology

Journal

F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320

Informations de publication

Date de publication:
2022
Historique:
accepted: 13 12 2022
entrez: 13 2 2023
pubmed: 14 2 2023
medline: 15 2 2023
Statut: epublish

Résumé

Synthetic lethal interactions (SLIs), genetic interactions in which the simultaneous inactivation of two genes leads to a lethal phenotype, are promising targets for therapeutic intervention in cancer, as exemplified by the recent success of PARP inhibitors in treating BRCA1/2-deficient tumors. We present SL-Cloud, a new component of the Institute for Systems Biology Cancer Gateway in the Cloud (ISB-CGC), that provides an integrated framework of cloud-hosted data resources and curated workflows to enable facile prediction of SLIs. This resource addresses two main challenges related to SLI inference: the need to wrangle and preprocess large multi-omic datasets and the availability of multiple comparable prediction approaches. SL-Cloud enables customizable computational inference of SLIs and testing of prediction approaches across multiple datasets. We anticipate that cancer researchers will find utility in this tool for discovery of SLIs to support further investigation into potential drug targets for anticancer therapies.

Identifiants

pubmed: 36761837
doi: 10.12688/f1000research.110903.2
pmc: PMC9880341.2
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

493

Subventions

Organisme : NCI NIH HHS
ID : U01 CA217883
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA077852
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201400008C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201500003I
Pays : United States

Informations de copyright

Copyright: © 2022 Tercan B et al.

Déclaration de conflit d'intérêts

No competing interests were disclosed.

Auteurs

Bahar Tercan (B)

Institute for Systems Biology, Seattle, WA, 98109, USA.

Guangrong Qin (G)

Institute for Systems Biology, Seattle, WA, 98109, USA.

Taek-Kyun Kim (TK)

Institute for Systems Biology, Seattle, WA, 98109, USA.

Boris Aguilar (B)

Institute for Systems Biology, Seattle, WA, 98109, USA.

John Phan (J)

General Dynamics Information Technology, Rockville, MD, 20852, USA.

William Longabaugh (W)

Institute for Systems Biology, Seattle, WA, 98109, USA.

David Pot (D)

General Dynamics Information Technology, Rockville, MD, 20852, USA.

Christopher J Kemp (CJ)

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.

Nyasha Chambwe (N)

Institute for Systems Biology, Seattle, WA, 98109, USA.
Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 11030, USA.

Ilya Shmulevich (I)

Institute for Systems Biology, Seattle, WA, 98109, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH